December 16, 2020 | From the Trenches
Over the course of my career in healthcare, I’ve been fortunate to serve in a leadership role through four IPOs and even more financing rounds. All told, I’ve raised well over $1.5 billion in capital. That means I’ve spent a lot of time thinking about dilution.
By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC
December 10, 2020 | From the Trenches
One of the biggest elephants in the room regarding starting and scaling young companies is the tension, often healthy but sometimes detrimental, that exist between CEOs and venture capital firms.
By Philip Astley-Sparke, CEO of Replimune, as part of the From The Trenches feature of LifeSciVC.
December 8, 2020 | From the Trenches
Prioritization is a concept that we have become intimately aware of, given the continually blurred lines of personal and professional obligations in a 24/7 world. The good news is we all know we need to prioritize; the bad news is we need to find time and courage to do it. In the fast-paced reality of drug development, that time needs to be sooner rather than later. Time can mean life and death for the patients we serve. Many biopharmaceutical companies face an abundance of riches in the scientific opportunities to explore but must contend with constraints in resources, both people and dollars. Given these constraints, a critical part of the development planning process needs to include prioritization of opportunities, whether they be diseases, targets, indications, or trials. But the real question is how do we manage this prioritization in a practical, collaborative, yet disciplined manner?
By Rene Russo, CEO of Xilio Therapeutics, as part of the From The Trenches feature of LifeSciVC
December 8, 2020 | In the News
After more than 20 years in the industry, Ivana Magovčević-Liebisch had done it all — except build a company from scratch. Then Bruce Booth at Atlas Venture mentioned a couple of TREM2 assets he was trying to snag from Amgen’s old neuroscience pipeline.
December 8, 2020 | In the News
Local life sciences investor Atlas Venture is continuing its push into RNA therapies with a new company: Remix Therapeutics.